ÂÜÀòÂÒÂ×

Pam Bruce-Staskal has over 30 years of experience in the field of biomolecular analytics and immunoassay development. Pam is currently the Associate Director of Biomolecular Analytics at BioFactura, Inc., where they lead a team in developing and optimizing analytical methods for therapeutic agents. Their expertise includes trouble-shooting, problem-solving, critical thinking, and data analysis, which enables their to effectively meet customer needs. Prior to their current role, Pam worked as a Principal Scientist at Paragon BioServices/Catalent, where they contributed to various scientific projects. Pam also served as a Principal Scientist at NOVAVAX INC, overseeing the ImmunoAssay Group in the Analytical Development Department. During this time, they developed and optimized analytical methods for RSV F, Zika virus EnvD, and influenza HA vaccines, following FDA, ICH, and EMA guidance. Earlier in their career, Pam worked as a Scientist III at Meso Scale Discovery, where they focused on immunoassay development on electrochemiluminescence-based detection systems. Pam collaborated with pharmaceutical companies and government agencies for the development of protein biomarker assays and infectious disease diagnostics. Pam started their career as a Senior Microbiologist at the Wisconsin State Laboratory of Hygiene.

Pam Bruce-Staskal holds a Doctor of Philosophy (PhD) degree in Microbiology, General, which they obtained from the University of Virginia in the period from 1996 to 2002. Prior to their doctoral studies, they pursued a Master of Science (MS) degree in Bacteriology from the University of Wisconsin-Madison, completed in 1995. In 1989, they earned their Bachelor of Science (BS) degree in Medical Microbiology and Immunology, also from the University of Wisconsin-Madison.